Takeda, Toyotas, and the Price of Japan's Export Machine

Two court cases, two Japanese industries, one uncomfortable headline: the country's export machine is generating friction it cannot easily absorb.

On 19 May 2026, a US jury found Takeda Pharmaceutical liable for an antitrust scheme designed to block a generic version of its constipation drug from entering the American market. The same day, Nikkei Asia reported that Japan's once-plentiful used car market is pricing out domestic buyers, squeezed by soaring wholesale costs and a yen that has made export markets — not Japanese consumers — the more profitable destination. Both stories are local in origin. Both are global in consequence.

The thread connecting them is not accidental. Japan's postwar economic architecture was built around a simple proposition: export or stagnate. That model served the country well through decades of trade surpluses, industrial upgrading, and technological leadership. But the pressures it creates — legal exposure in foreign jurisdictions, domestic shortages in sectors re-routed toward foreign buyers — are increasingly difficult to paper over with the rationale that growth justifies everything.

The Takeda verdict and the cost of market gatekeeping

Takeda's case is instructive because the misconduct was not subtle. A US jury found the company engaged in a deliberate scheme to delay generic competition for a constipation treatment — a drug whose efficacy had long since been established, whose patent runway had expired, and whose generic alternatives were held off the market through practices that violated American competition law. The jury verdict signals that US courts are increasingly willing to treat pharmaceutical delay tactics as antitrust violations rather than standard intellectual property strategy.

For Japan's pharmaceutical sector, this matters. Takeda is the country's largest drugmaker by revenue, a global institution with deep ties to the Japanese regulatory apparatus. A foreign court finding it liable for market gatekeeping is not a regulatory footnote — it is a signal about how far Japanese corporate practice can stretch before it collides with the legal systems of the markets it serves. The yen weakness that makes Takeda's export revenues more valuable in yen terms does not insulate it from American jury verdicts.

Yen, exports, and the disappearing cheap used car

The used car story is lower-stakes in legal terms but more revealing structurally. Japan exported a record number of used cars last year, driven by a weak yen that made Japanese vehicles cheap in foreign markets and by demand from right-hand-drive markets across Asia, Africa, and the Pacific. That export surge is a symptom of the same export-dependency that animates Japanese industrial policy: when the currency is cheap, selling abroad beats selling at home.

But Nikkei Asia reported that this dynamic is now crowding out Japanese domestic buyers. Wholesale prices for used vehicles have surged. Domestic consumers — particularly lower-income households, rural families, and first-car buyers — find themselves priced out of a market that is functioning exactly as the export model intends. The weak yen that helps Japanese exporters also makes the domestic used car market a reseller's market rather than a buyer's one. This is not a failure of the market. It is the market working as designed — for the buyers who can afford to play in it.

The structural tension

What both cases expose is a recurring contradiction in Japan's economic model. The country built its prosperity on export orientation, and export orientation requires price competitiveness — and price competitiveness, in a world of floating exchange rates, means a weaker yen. But weaker yen dynamics do not stay contained within the export sector. They flow into domestic markets, raise input costs for Japanese firms, and shift the terms of trade away from Japanese consumers toward foreign buyers.

Similarly, the pressure to perform in export markets — to protect revenue streams, to maintain pricing power, to hold market share — creates incentives for corporate behavior that sits uneasily in the jurisdictions where Japanese companies sell. Takeda did not run an antitrust scheme for fun. It did it to protect a revenue stream that depended on keeping a branded drug on the market after its patent position had been weakened. That logic is comprehensible from a corporate finance perspective. It is less comprehensible from an antitrust perspective, and an American jury agreed.

The broader question is whether Japan's corporate culture — still organized around long-tenure employment, consolidated banking relationships, and an implicit understanding that the country's champion firms operate inside a framework where domestic interests take priority — is equipped to navigate the dual pressure of foreign legal accountability and the domestic distortions that export-dependency creates. The evidence from this week's court cases suggests the answer is no, at least in the cases that have come to light.

What comes next

Takeda faces exposure beyond the jury verdict — civil damages, regulatory scrutiny, and likely increased pressure from US authorities to restructure how it manages generic competition for off-patent drugs. For the used car market, the dynamics are more diffuse but no less significant: Japan's export surge is visible to trading partners, many of whom are already reviewing their own import regimes for used vehicles. Both cases will attract scrutiny from regulators and trading partners who see Japan's export machine as occasionally operating by rules that differ from the ones it signs up to.

The uncomfortable truth is that both Takeda's antitrust liability and the used car export surge are products of the same underlying impulse — the drive to maximize returns from Japan's industrial base, regardless of the knock-on effects on the markets, consumers, and legal systems that make those returns possible. Japan's export model has delivered enormous wealth. It has also built in contradictions that are increasingly surfacing in foreign courtrooms and domestic price spikes. That contradiction will not resolve itself.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• http://reut.rs/49tsFr1